Abstract
Lung cancer is the leading cause of mortality due to tumor malignancy worldwide. In recent years, the treatment of lung cancer with chemotherapy has demonstrated notable resistance and insensitivity. Therefore, it is of great importance to investigate anti‑lung cancer drugs with high efficiency and low toxicity. In the present study, the effects of isofraxidin on lung cancer cells and the associated mechanisms were investigated. The results revealed that, in vivo and in vitro, isofraxidin exhibited marked inhibitory effects on the A549 lung cancer cell line. The results of Cell Counting kit‑8, Transwell migration and Matrigel invasion assays, and flow cytometry to determine apoptosis, revealed that isofraxidin significantly inhibited the proliferation, migration and invasion of A549 cells, and induced the cell apoptosis. Furthermore, western blot analysis demonstrated that isofraxidin treatment led to effects on the expression of apoptosis‑associated proteins, including members of the Bcl‑2 protein family, and invasion‑associated proteins, including matrix metallopeptidase (MMP)‑2 and MMP‑9, which may occur via inhibition of the expression of phosphorylated (p)‑epidermal growth factor receptor, p‑AKT and p‑extracellular signal‑...Continue Reading
References
Jan 30, 2009·Journal of Asian Natural Products Research·Shafiullah KhanMehreen Lateef
Feb 26, 2009·Journal of Carcinogenesis·Neelu Puri, Ravi Salgia
Mar 17, 2010·Phytochemistry Letters·Li PanA Douglas Kinghorn
Apr 8, 2010·Cell·Kai KessenbrockZena Werb
Oct 12, 2010·Biological & Pharmaceutical Bulletin·Taisuke Yamazaki, Takayoshi Tokiwa
Oct 19, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Alex Chang
Mar 19, 2011·Cell·Sabrina L Spencer, Peter K Sorger
Jul 18, 2012·International Immunopharmacology·Xiaofeng NiuYongmei Li
Jul 27, 2012·Archives of Gynecology and Obstetrics·Xiaoxia HuLi Li
Mar 29, 2014·Cell Biology International·Lingli ZhouDonald C Chang
Jan 18, 2015·International Immunopharmacology·Xiaofeng NiuHailin Zhang
Jan 16, 2016·The Oncologist·Glenwood D Goss, Johanna N Spaans
Aug 9, 2016·Molecular Medicine Reports·Huiqiang WangXinyi Wu
Sep 17, 2016·Cancer Research·Lixing ZhangJinjun Li
Oct 26, 2016·Molecular Medicine Reports·Lin YangTadashi Hisamitsu
Oct 26, 2016·Oncotarget·Lihong BaiCanmao Xie
Jan 11, 2017·Journal of Cell Communication and Signaling·Mario A CepedaSashko Damjanovski
Feb 6, 2017·Cell Biology International·Weiwen LiJialu Zhao
Feb 24, 2017·Journal of Cancer Research and Therapeutics·Kaixian Zhang, Qianqian Yuan
Apr 13, 2017·Cancer Letters·Lili WangTonghua Liu
May 23, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Peng ShenRui Xie
Jun 8, 2017·Experimental and Therapeutic Medicine·Yitao WanYing Zhang
Jul 14, 2017·Anti-cancer Drugs·Yanmao WangYimin Chai
Jul 16, 2017·Targeted Oncology·Yvette N Lamb, Lesley J Scott
Jul 18, 2017·Oncology Reports·Shiping HuYongjian Xu
Sep 17, 2017·Oncotarget·Leong-Perng ChanChia-Hua Liang
Nov 25, 2017·Cytotechnology·Liqiang QianGenhai Shen